Y-mAbs Therapeutics announced new clinical and preclinical data from studies evaluating naxitamab and GD2-SADA, respectively, in neuroblastoma. The results are summarized in poster presentations scheduled to be presented September 6 – 7, 2024, at the American Academy of Cancer Research, AACR, Special Conference in the Advances in Pediatric Cancer Research in Toronto, Canada. Naxitamab maintains disease control in patients with refractory/relapsed high-risk neuroblastoma: Patients with refractory/relapsed high-risk neuroblastoma and residual disease in the bone and/or bone marrow who were treated with naxitamab in combination with granulocyte-macrophage colony-stimulating factor achieved a disease control rate of 63%. High-affinity binding of GD2-SADA to Tb-DOTA: The study demonstrated tight binding interactions between GD2-SADA and DOTA-chelated terbium, a metal in the same lanthanide family as lutetium with multiple medical isotopes of potential benefit in diagnosis and therapy. The results have informed ongoing PK/PD modeling and the initial dosing in Trial 1001
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on YMAB:
- Y-mAbs to Participate in Upcoming Investor Conferences in September
- Cisco, Nike upgrades among today’s top calls on Wall Street
- Cantor starts Y-mAbs with Overweight on pivot to radiopharmaceuticals
- Y-mAbs Therapeutics initiated with an Overweight at Cantor Fitzgerald
- Y-mAbs Therapeutics price target lowered to $11 from $12 at Morgan Stanley